- Home
- Technology & AI
- Dexcom G7, prick-less, real-ti ...

Dexcom has just launched its latest continuous glucose monitor (CGM) the G7 with which it plans to expand its market from type 1 to type 2 diabetes patients. The G7 is a device made up of sensors that attach themselves to the patient’s arm and measure blood glucose levels from under the skin for up to 10 days after which the device can be disposed of. This means that patients no longer need to prick their skin or go for continuous tests to keep a check on their glucose levels.
Compared to the Dexcom G6 that came in 2018, the newer model contains features such as an up to 60% reduction in size and a 30-minute sensor warm-up, which is the lowest for any CGM currently available on the market. In addition, the new G7 is more discreet and wearable and acts as a one-stop for all as it includes a combined applicator and transmitter.
A notable part of the Dexcom G7 is that it was designed after taking input from Dexcom customers around the world, patients and caregivers were consulted to come up with technology that facilitated the everyday life of all people involved.
“When the G6 was introduced, it revolutionized the market and helped improve the quality of care for over a million people, the new G7 will build on this legacy,” said Kevin Sayer, CEO of Dexcom.
The technology is now available for sale in the UK and different parts of Europe such as Germany and Austria. In the U.K. alone there are around 5 million diabetes patients and the number is only expected to increase in the future. Soon, Dexcom also plans to expand to New Zealand and South Africa.
Apart from this, Dexcom also has FDA approval to connect the blood sugar data it collects through its devices to third-party fitness trackers such as Livongo and Garmin which will allow the company to connect with users’ fitness and well-being on a deeper level. Moreover, the company has also been working on entering hospital use and after FDA approval in March, the device can now be used by patients for the duration of their hospital stays.
In Europe, Dexcom has also dabbled in its dual product strategy, in the UK and Spain, the company is selling a simpler version of its G6 technology with fewer automatic features and simpler programming called Dexcom One.
However, there have been some delays for Dexcom launches in the U.S. where the G7 was initially submitted for an FDA review in 2021. It was sent for FDA review once again this summer and a nationwide launch is expected by 2023. The software submitted in the new review is different from the old one as it allows the G7 to send alarms to smartphones that would update users on any changes in their glucose levels.
Profits from the G7 and Dexcom together are expected to raise the company’s total revenue to $2.94 billion from $2.82 billion. This shows an up to 20% annual growth rate.